|
Phentolamine
resources
|
|
|
|
|
|
DRUG INFO
Phentolamine
Drug Name:
Phentolamine
Indication: Female sexual dysfunction
Pharmacology: Phentolamine is indicated for the control of episodes of hypertension and sweating that occur with a disease called pheochromocytoma. If tachycardia is excessive, it may be necessary to use a beta-blocking agent concomitantly. Phentolamine is a long-acting, adrenergic, alpha-receptor blocking agent which can produce and maintain "chemical sympathectomy" by oral administration. It increases blood flow to the skin, mucosa and abdominal viscera, and lowers both supine and erect blood pressures. It has no effect on the parasympathetic system. Phentolamine works by blocking alpha receptors in certain parts of the body. Alpha receptors are present in the muscle that lines the walls of blood vessels. When the receptors are blocked by Phentolamine, the muscle relaxes and the blood vessels widen. This widening of the blood vessels results in a lowering of blood pressure.
Mechanism Of Action: Phentolamine produces its therapeutic actions by blocking alpha receptors, leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure.
Drug Category: Antihypertensive Agents; Sympatholytics; ATC:C04AB01; ATC:G04BE05
Brand Names/Synonyms: Phenotolamine; Phentalamine; Phentolamine Mesilate; Phentolamine Mesylate; Phentolamine Mesylate [Usan]; Phentolamine Methanesulfonate; Phentolamine Methanesulphonate; Phentolamine, Methyl Sulfonate; Regitin; Regitin Methanesulphonate; Regitine; Regitine Mesylate; Regitine Methanesulfonate; Regitipe; Rogitine
Dosage Forms: LIQUID
Absorption: Not Available
Interactions: Interactions for Phentolamine:
Diagnosis of pheochromocytoma - phentolamine blocking test.
The test is most reliable in detecting pheochromocytoma in patients with sustained hypertension and least reliable in those with paroxysmal hypertension. False-positive tests may occur in patients with hypertension without pheochromocytoma.
Chemical IUPAC Name: 3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)-amino]phenol
Chemical Formula: C17H19N3O
Half Life: 19 minutes
Drug Type: Approved Drug
# Accession No: APRD00615
CAS Registry Number: 50-60-2
|
|
|
|
|
|
Phentolamine News
(When available)
Novel Drug Pradefovir Mesylate May Emerge as Treatment Option in ... Dec 15, 2005
DG News KOHALA COAST, HI -- December 15, 2005 -- A novel cytochrome, pradefovir mesylate P450 (PDV), might become a viable treatment option for patients with hepatitis ...
Imatinib mesylate is not likely to be effective for patients with ... Dec 21, 2005
RxPG NEWS, By Mayo Clinic, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal ...
Imatinib mesylate (Gleevec) may not be effective at treating ... Dec 21, 2005
News-Medical.net, Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs ...
Dishman to expand EM capacity to 7.2mt Jan 12, 2006
Business Standard, Dishman Pharmaceuticals plans to increase installed capacity of its Eprosartan Mesylate (EM) plant from 6. MT to 7.2 MT per month to meet the future demand of ...
Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ... Jan 9, 2006
Genetic Engineering News, ...quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin mesylate) tablets, and ...
Bio-IT Briefs Jan 12, 2006
Bio-IT World, ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec (imatinib mesylate). ...
INNOVIVE Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase ... Jan 5, 2006
Business Wire (press release), 1, 2005), NS-187 is 25 to 55 times more potent than imatinib mesylate (Gleevec(TM)) in vitro, and at least 10 times as effective as imatinib mesylate in ...
Oscient Pharmaceuticals to Present at 24th Annual JPMorgan ... Jan 3, 2006
Genetic Engineering News, CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate) tablets, the ...
Infinity Initiates Phase I Clinical Trial of IPI-504 for Patients ... Jan 10, 2006
PR Newswire (press release), ...pharmacokinetic profile and potential efficacy of IPI-504 in patients with gastrointestinal stromal tumors (GIST) resistant to Gleevec(R) (imatinib mesylate). ...
Effectiveness of Gleevec® Plus Hydroxyurea for Treatment of ... Dec 22, 2005
Cancer Consultants (press release), ...from the University of Pittsburgh, Dulman, Germany, and Duke University have reported that the combination of Gleevec (imatinib mesylate) plus hydroxyurea ...
Pharmaceutical Industry Marketing and Sales Veteran to Lead ... Jan 4, 2006
PharmaLive.com (press release), ...products. He led the launch of Synthon's first branded drug, Pexeva(r) (paroxetine mesylate) into the SSRI depression market. Prior ...
Vaccine for Chronic Myeloid Leukemia Active in Patients with ... Jan 5, 2006
Business Wire (press release), ...of positive interim data for a novel vaccine known as VAX100 for patients with persistent chronic myeloid leukemia (CML) while on imatinib mesylate (Gleevec(R ...
New Pharmaceutical Treatment Options in the Elderly Dec 14, 2005
Medscape (subscription) Gemifloxacin mesylate (Factive). Gemifloxacin mesylate, which is given daily (320 mg for 5 to 7 days), is a new fluoroquinolone ...
Drug questionable in some kidney cancers Dec 22, 2005
United Press International The drug in question, imatinib mesylate, used to treat patients with gastrointestinal stromal cancers, is said not likely to be effective for patients with high ...
Vaccine Shows Promise Against Residual Chronic Myeloid Leukemia Dec 27, 2005
Cancer Consultants (press release), Use of a cancer vaccine after treatment with Gleevec® (imatinib mesylate) may reduce or eliminate residual leukemia in some patients with chronic myeloid ...
Investigational Drug Shows Promise in Gleevec®-Resistent CML Dec 29, 2005
Cancer Consultants (press release), AMN107 has produced treatment responses in some patients with chronic myeloid leukemia (CML) that does not respond to Gleevec® (imatinib mesylate), as well as ...
Treatment with Gleevec® Continues to Show Benefits in CML Dec 28, 2005
Cancer Consultants (press release), ...to updated study results presented at the 47th annual meeting of the American Society of Hematology (ASH), Gleevec® (imatinib mesylate) produces good long ...
Mayo Clinic Finds Kidney Cancer Patients Unlikely to Respond to ... Dec 22, 2005
DG News ROCHESTER, MN -- December 22, 2005 -- Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with ...
Ramoplanin Demonstrates High Activity Against Wide Array of ... Dec 19, 2005
PharmaLive.com (press release), The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ... Dec 20, 2005
Cancer Consultants (press release), ...to a recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus hydroxyurea ...
Desatinib Promising for Patients with CML Who Do Not Respond to ... Dec 23, 2005
Cancer Consultants (press release), ...still in clinical trials, is an effective treatment option for patients with chronic myelogenous leukemia (CML) who do not respond to Gleevec (imatinib mesylate ...
Glivec Seeking to Become First Targeted Treatment for Adult ... Dec 13, 2005
PharmaLive.com (press release), December 13, 2005 – Novartis has submitted a marketing authorization application for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) tablets in ...
Restless Legs Syndrome Fact Sheet Dec 14, 2005
Community Dispatch (press release) Dopamine agonists such as pergolide mesylate, pramipexole, and ropinirole hydrochloride may be effective in some patients and are less likely to cause ...
Cell Genesys Reports Positive Results from Phase 2 Trial of GVAX ... Dec 12, 2005
DG News Nineteen CML patients with molecular evidence of persistent leukemia despite more than 1 year of Gleevec(R) (imatinib mesylate) therapy were treated with GVAX ...
|
|
|
